<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080908</url>
  </required_header>
  <id_info>
    <org_study_id>19-00866</org_study_id>
    <nct_id>NCT04080908</nct_id>
  </id_info>
  <brief_title>Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support</brief_title>
  <acronym>AMAGFeraheme</acronym>
  <official_title>Open Label Single Arm Pilot Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ferumoxytol injection (FerahemeÂ®) is a parenteral form of iron supplementation that is
      FDA-approved for treatment of iron deficiency anemia. Ferumoxytol injection achieves iron
      repletion in fewer doses (2) when compared with other available injectable iron formulations
      (5-6) available at NYU Langone Health, and thus may be useful to reduce travel burden and
      expedite full iron repletion in patients with iron deficiency. Iron-deficiency anemia is
      common in patients after placement of a ventricular assist device (VAD) for treatment of
      end-stage heart disease. This is a pilot study to test the feasibility of iron repletion with
      ferumoxytol injection in 20 eligible subjects with laboratory evidence of iron deficiency
      after placement of a VAD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who successfully complete ferumoxytol injection treatment</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Ferumoxytol injection treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol injection</intervention_name>
    <description>Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.</description>
    <arm_group_label>Ferumoxytol injection treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Status post placement of durable ventricular assist device with stable clinical status
             for &gt;30days

          -  Hemoglobin &gt;6 g/dL AND &lt;13 g/dL (men) or &lt;12 g/dL (women) within last 90 days

          -  Serum ferritin &lt;100 ng/mL OR Serum ferritin 100-299 ng/mL with transferrin saturation
             &lt;20% within last 90 days

          -  Able and willing to provide written informed consent

        Exclusion Criteria:

          -  Known hypersensitivity to Ferumoxytol injection or other intravenous iron preparation

          -  History of anaphylaxis

          -  Treatment with erythropoiesis stimulating agent or intravenous iron in last 3 months

          -  Renal failure on hemodialysis

          -  Respiratory failure on mechanical ventilation

          -  Disabling Stroke

          -  Ventricular assist device thrombosis

          -  Evidence of active gastrointestinal bleeding or other active blood loss

          -  Hospitalization &lt;30 days

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Langone Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sevinj Sasunova</last_name>
    <phone>212 263 4113</phone>
    <email>Sevinj.Sasunova@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sevinj Sasunova</last_name>
      <phone>212-263-4113</phone>
      <email>Sevinj.Sasunova@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Stuart Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

